Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT03361163Phase 1Completed
Phase 1, open-label, single-arm trial. Primary endpoint: Proportion of participants at each GAS M75 dose level meeting the study pharyngitis endpoint at 6 days. Started Jul 2018; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT03361163.